Mesoblast limited (NASDAQ:MESO) has earned a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $13.40.
MESO has been the topic of a number of research analyst reports. ValuEngine lowered Yirendai from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 26th. Maxim Group set a $3.00 price target on Biopharmx and gave the stock a “buy” rating in a research note on Wednesday, June 12th. Chardan Capital set a $6.00 price target on Mesoblast and gave the stock a “hold” rating in a research note on Friday, May 31st. HC Wainwright reaffirmed a “buy” rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. Finally, Zacks Investment Research downgraded Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th.
Shares of NASDAQ:MESO traded up $0.01 during trading on Friday, reaching $5.25. The stock had a trading volume of 10,778 shares, compared to its average volume of 79,524. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.14. The stock has a fifty day moving average of $5.09. The company has a market cap of $494.40 million, a PE ratio of -8.33 and a beta of 1.86. Mesoblast has a 1-year low of $3.35 and a 1-year high of $8.78.
A hedge fund recently raised its stake in Mesoblast stock. Jane Street Group LLC raised its holdings in shares of Mesoblast limited (NASDAQ:MESO) by 590.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,073 shares of the company’s stock after acquiring an additional 89,010 shares during the quarter. Jane Street Group LLC owned approximately 0.11% of Mesoblast worth $426,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.76% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: Preferred Stock
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.